HIV TREATMENT
2020
Action 27. Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.
Action 34. Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.
Paediatric HIV & TB : Rome Action Plan
Only fund the procurement of drugs and formulations recommended by WHO on the Optimal Formulary List
PEPFAR, UNITAID
Request policy statement from PEPFAR and Global Fund on exclusive funding of Optimal Formulary List
-
Since 2017, PEPFAR has taken direct action to ensure that PEPFAR funds are not used to purchase ARVs that are no longer standard of care.
In its COP18 guidance, PEPFAR highlighted its support for use of preferred, child-friendly formulations: “For children, PEPFAR supports use of currently preferred regimens (e.g. lopinavir/ritonavir-based first-line regimens for children under 3 years old or 30 kg.) in child-friendly formulations and will support rapid introduction of new drugs and formulations for children (e.g.dolutegravir) as they become available and recommendations are updated. “ [page 56, https://www.pepfar.gov/reports/guidance/c77910.htm ]
PEPFAR funds can no longer be used to purchase nevirapine products for treatment in older children and adults.
Global Fund applies strict rules on optimal procurement. Wambo site only shows optimal drugs and formulations
-
-
-
-